Vertex Pharmaceuticals Inc

-2.64 (-0.79%)


Draw Mode:

Volume 1,850,547
Bid Price 325.43
Ask Price 336.19
News -
Day High 331.78


52 Week Range


Day Low 325.82
Company Name Stock Ticker Symbol Market Type
Vertex Pharmaceuticals Inc VRTX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-2.64 -0.79% 329.99 00:00:09
Open Price Low Price High Price Close Price Prev Close
329.23 325.82 331.78 329.99 332.63
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
38,453 1,850,547 $ 329.48 $ 609,716,134 - 243.17 - 354.46
Last Trade Time Type Quantity Stock Price Currency
19:57:05 2 $ 333.87 USD

Vertex Pharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 85.00B 257.59M 256.51M $ 2.37B $ 6.89M 2.72 12,342.52
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 108.20k 0.20%

more financials information »

Vertex Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No VRTX Message Board. Create One! See More Posts on VRTX Message Board See More Message Board Posts

Historical VRTX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week341.37345.805325.82335.771,160,606-11.38-3.33%
1 Month338.50354.46325.82342.791,092,644-8.51-2.51%
3 Months290.52354.46283.60321.711,084,69239.4713.59%
6 Months313.78354.46282.21311.301,245,41016.215.17%
1 Year270.84354.46243.17299.161,357,74359.1521.84%
3 Years288.00354.46176.36245.281,685,66141.9914.58%
5 Years156.60354.46144.07227.821,566,968173.39110.72%

Vertex Pharmaceuticals Description

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.